According to the companies, with its new members the partnership will now be able to support the development and manufacture of complex ADCs from drug substance to final drug product.
PROVEO also offers project management, supply chain system, and quality systems.
As part of the partnership, CMC Biologics provides monoclonal antibody production and IDT Biologika performs analytical services, supply chain and secondary packaging through to final drug product.
Moving forward, Cerbios will carry out process development, manufacture of the cytotoxic drug-linker payload, in addition to providing conjugation services of the ADC drug substance. Oncotec will provide aseptic fill and lyophilization of the ADC drug product.
The services will be available through the PROVEO Partnership in early 2017.